Work horse gene therapy
GeneQuine's gene therapy could achieve sustained IL-1 blockade for osteoarthritis
GeneQuine Biotherapeutics GmbH is developing a gene therapy for osteoarthritis that provides sustained expression of an IL-1 antagonist in joints and could improve on the marginal efficacy seen with transient anti-IL-1 therapies.
GQ-201 is a helper-dependent adenoviral (HDAd) vector encoding an equine IL-1 receptor antagonist (IL-1RA) to treat osteoarthritis (OA) in horses. The company plans to use horse data to support clinical development of its human IL-1RA gene therapy, GQ-203, for the same indication...